Literature DB >> 29953902

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.

Stefano Aringhieri1, Marco Carli1, Shivakumar Kolachalam1, Valeria Verdesca1, Enrico Cini1, Mario Rossi2, Peter J McCormick3, Giovanni U Corsini1, Roberto Maggio4, Marco Scarselli5.   

Abstract

The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only in terms of hospitalization and reduction in symptoms severity, but also in terms of safety, socialization and better rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D2 receptor antagonists and they act beyond D2 antagonism, involving other receptor targets which regulate dopamine and other neurotransmitters. Consequently, AAPs present a significant reduction of deleterious side effects like parkinsonism, hyperprolactinemia, apathy and anhedonia, which are all linked to the strong blockade of D2 receptors. This review revisits previous and current findings within the class of AAPs and highlights the differences in terms of receptor properties and clinical activities among them. Furthermore, we propose a continuum spectrum of "atypia" that begins with risperidone (the least atypical) to clozapine (the most atypical), while all the other AAPs fall within the extremes of this spectrum. Clozapine is still considered the gold standard in refractory schizophrenia and in psychoses present in Parkinson's disease, though it has been associated with adverse effects like agranulocytosis (0.7%) and weight gain, pushing the scientific community to find new drugs as effective as clozapine, but devoid of its side effects. To achieve this, it is therefore imperative to characterize and compare in depth the very complex molecular profile of AAPs. We also introduce relatively new concepts like biased agonism, receptor dimerization and neurogenesis to identify better the old and new hallmarks of "atypia". Finally, a detailed confrontation of clinical differences among the AAPs is presented, especially in relation to their molecular targets, and new means like therapeutic drug monitoring are also proposed to improve the effectiveness of AAPs in clinical practice.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical antipsychotics; Biased agonism; Clozapine; Dimerization; Monoamine receptors; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2018        PMID: 29953902     DOI: 10.1016/j.pharmthera.2018.06.012

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  41 in total

Review 1.  Recent advances and perspectives of postoperative neurological disorders in the elderly surgical patients.

Authors:  Biying Liu; Dan Huang; Yunlu Guo; Xiaoqiong Sun; Caiyang Chen; Xiaozhu Zhai; Xia Jin; Hui Zhu; Peiying Li; Weifeng Yu
Journal:  CNS Neurosci Ther       Date:  2021-12-03       Impact factor: 5.243

Review 2.  Progress in mechanistically novel treatments for schizophrenia.

Authors:  James Neef; Daniel S Palacios
Journal:  RSC Med Chem       Date:  2021-06-29

3.  Transcriptome analysis of human induced excitatory neurons supports a strong effect of clozapine on cholesterol biosynthesis.

Authors:  Debamitra Das; Xi Peng; Anh-Thu N Lam; Joel S Bader; Dimitrios Avramopoulos
Journal:  Schizophr Res       Date:  2021-01-24       Impact factor: 4.939

4.  Effects of Haloperidol, Risperidone, and Aripiprazole on the Immunometabolic Properties of BV-2 Microglial Cells.

Authors:  Valentino Racki; Marina Marcelic; Igor Stimac; Daniela Petric; Natalia Kucic
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

5.  Proteome Analysis of PC12 Cells Reveals Alterations in Translation Regulation and Actin Signaling Induced by Clozapine.

Authors:  Urszula Jankowska; Bozena Skupien-Rabian; Bianka Swiderska; Gabriela Prus; Marta Dziedzicka-Wasylewska; Sylwia Kedracka-Krok
Journal:  Neurochem Res       Date:  2021-05-23       Impact factor: 3.996

6.  The Antipsychotic Drug Clozapine Suppresses the RGS4 Polyubiquitylation and Proteasomal Degradation Mediated by the Arg/N-Degron Pathway.

Authors:  Jun Hyoung Jeon; Tae Rim Oh; Seoyoung Park; Sunghoo Huh; Ji Hyeon Kim; Binh Khanh Mai; Jung Hoon Lee; Se Hyun Kim; Min Jae Lee
Journal:  Neurotherapeutics       Date:  2021-04-21       Impact factor: 6.088

Review 7.  Current Concepts and Treatments of Schizophrenia.

Authors:  Piotr Stępnicki; Magda Kondej; Agnieszka A Kaczor
Journal:  Molecules       Date:  2018-08-20       Impact factor: 4.411

Review 8.  Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications.

Authors:  Amber N Edinoff; Nancy S Silverblatt; Hayley E Vervaeke; Cassidy C Horton; Eden Girma; Alan D Kaye; Adam Kaye; Jessica S Kaye; Andrew J Garcia; Elisa E Neuchat; Treniece N Eubanks; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16

9.  Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.

Authors:  Igne Sinkeviciute; Kenneth Hugdahl; Christoffer Bartz-Johannessen; Rune Andreas Kroken; Else-Marie Løberg; Eirik Kjelby; Maria Anna Rettenbacher; Inge Joa; Solveig Klæbo Reitan; Renata Alisauskiene; Farivar Fathian; Erik Johnsen
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

10.  Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?

Authors:  Thanh Phuong Pham Nguyen; Danielle S Abraham; Dylan Thibault; Daniel Weintraub; Allison W Willis
Journal:  BMC Neurol       Date:  2021-06-24       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.